BIRC5 and cancer: The anticancer and chemosensitizing effects of spironolactone on various types of cancer cells appear to be attributed to survivin reductions, and the suppression of survivin is a novel mechanism for the chemosensitizing effects of spironolactone in combination with non-DNA-damaging chemotherapeutic drugs, such as gemcitabine and osimertinib.